Scalper1 News
Generic-drug maker and IBD 50 stock Akorn (AKRX) on Thursday reported Q3 results complicated by accounting issues, sending the stock down nearly 11% in afternoon trade on the stock market today . The company’s revenue totaled $132.7 million, up 62% from the year-earlier quarter. The figure included $39.9 million in costs related to price increases on anti-rash cream clobetasol, which the company previously guided at $25 million. Without that cost, Scalper1 News
Scalper1 News